Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Jun 24, 2015
Insider Transaction Report
Form 4
Mirovsky Pavel
President of Valeant Europe
Transactions
- Award
Common Stock, no par value
2015-06-23+5,000→ 69,525 total
Footnotes (3)
- [F1]This number represents common shares ("Common Shares") of Valeant Pharmaceuticals, Inc. ("Valeant") issued upon vesting of performance-based RSUs ("PSUs").
- [F2]This number includes the maximum number of Common Shares that may be delivered in settlement of performance-based Restricted Share Units ("PSUs") that were previously reported on Form 4 in Table II. See note (3).
- [F3]The initial grant of PSUs was reported to vest based on total shareholder return ("TSR") between a price of $54.15 starting on May 15, 2012 and the average stock price for the 20 trading days starting on each measurement dates: 25% on February 15, 2015, 50% May 15, 2015 and 25% on August 15, 2015 (or 25% on February 15, 2016, 50% on May 15, 2016 and 25% on August 15, 2016, if applicable). Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs remain unvested for up to 2,500 Common Shares.